PMC3095904_01
The results of the pulmonary function tests three months before admission.
JA2011-479129.001.jpg
PMC3095904_01_JA2011-479129.001.jpg
fig1
Pulmonary function tests, which had been conducted three months before admission, showed a pattern of obstruction (Figure 1). 
The clinical course. (SFC: fluticasone/salmeterol, LVFX: levofloxacin, and PAPM/BP: panipenem/betamipron.)
JA2011-479129.002.jpg
PMC3095904_01_JA2011-479129.002.jpg
fig2
Next, 300 mg per day of omalizumab was administered; however, her dyspnea persisted (Figure 2) and her chest radiograph showed atelectasis of the left lung (Figure 3).
A chest radiograph showed atelectasis of the left lung.
JA2011-479129.003.jpg
PMC3095904_01_JA2011-479129.003.jpg
fig3
Next, 300 mg per day of omalizumab was administered; however, her dyspnea persisted (Figure 2) and her chest radiograph showed atelectasis of the left lung (Figure 3).
A chest radiograph showed an improvement in the atelectasis of the left lung.
JA2011-479129.004.jpg
PMC3095904_01_JA2011-479129.004.jpg
fig4
Her symptoms and respiratory status did not change during the first week, but, thereafter, the atelectasis improved (Figure 4).